코로나 19 후 폐섬유화(Post COVID-19 pulmonary fibrosis)에 대한 복합 한의치험 1례
Korean Medicine Treatment for a Patient with Post-COVID-19 Pulmonary Fibrosis: A Case Report
1
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background: Post-COVID-19 pulmonary fibrosis (PCPF) is a common complication in severe COVID-19 cases, often associated with acute respiratory distress syndrome or mechanical ventilation. Patients with PCPF frequently experience a decline in their quality of life due to persistent COVID-19 sequelae, including cough and chest pain. However, there is currently no established standard treatment, and the efficacy of existing medications remains uncertain. Case Report: A 65-year-old female patient presenting with cough, dyspnea, chest pain, and fatigue due to PCPF received Korean medicine treatment for 25 days. Symptom evaluation utilized the modified Medical Research Council scale, the Leicester Cough Questionnaire, and the Numeral Rating Scale. Quality of life and functional status were assessed using the Post-COVID-19 Functional Status and the EuroQol 5-Dimensional 5-Level. The extent of pulmonary fibrosis was assessed by comparing chest computed tomography (chest CT) scans before and after hospitalization. Following treatment, the patient demonstrated clinically meaningful improvement in clinical symptoms, enhanced quality of life, and decreased fibrotic lesions on CT scans. Conclusion: This case report suggests that Korean medicine treatment may be effective in improving clinical symptoms, such as cough and dyspnea caused by PCPF, while also enhancing post-COVID-19 quality of life and ameliorating pulmonary fibrotic lesions.
Abstract
Background: Post-COVID-19 pulmonary fibrosis (PCPF) is a common complication in severe COVID-19 cases, often associated with acute respiratory distress syndrome or mechanical ventilation. Patients with PCPF frequently experience a decline in their quality of life due to persistent COVID-19 sequelae, including cough and chest pain. However, there is currently no established standard treatment, and the efficacy of existing medications remains uncertain. Case Report: A 65-year-old female patient presenting with cough, dyspnea, chest pain, and fatigue due to PCPF received Korean medicine treatment for 25 days. Symptom evaluation utilized the modified Medical Research Council scale, the Leicester Cough Questionnaire, and the Numeral Rating Scale. Quality of life and functional status were assessed using the Post-COVID-19 Functional Status and the EuroQol 5-Dimensional 5-Level. The extent of pulmonary fibrosis was assessed by comparing chest computed tomography (chest CT) scans before and after hospitalization. Following treatment, the patient demonstrated clinically meaningful improvement in clinical symptoms, enhanced quality of life, and decreased fibrotic lesions on CT scans. Conclusion: This case report suggests that Korean medicine treatment may be effective in improving clinical symptoms, such as cough and dyspnea caused by PCPF, while also enhancing post-COVID-19 quality of life and ameliorating pulmonary fibrotic lesions.
참고문헌 (43)
- Alkodaymi MS, "Prevalence of post-acute COVID-19 syndrome symptoms at different follow-up periods : a systematic review and meta-analysis", Clin Microbiol Infect, 28(5), pp.657~666 (2022)
- 김윤정, "COVID-19와 장기 후유증", 대한내과학회지, 97(1), pp.23~27 (2022), 대한내과학회[DOI]
- Ambardar SR, "Post-COVID-19Pulmonary Fibrosis : Novel Sequelae of the Current Pandemic", J Clin Med, 10(11), pp.2452~ (2021)
- Michalski JE, "From ARDS to pulmonary fibrosis: the next phase of the COVID-19 pandemic?", Transl Res, 241, pp.13~24 (2022)
- Patrucco F, "Idiopathic Pulmonary Fibrosis and Post-COVID-19 Lung Fibrosis : Links and Risks", Microorganisms, 11(4), pp.895~ (2023)
- Mohammadi A, "Post-COVID-19Pulmonary Fibrosis", Cureus, 14(3), pp.e22770~ (2022)
- Saiphoklang N, "The Effect of Nintedanib in Post-COVID-19Lung Fibrosis : An Observational Study", Critical Care Research and Practice, 2022, pp.9972846~ (2022)
- Farghaly S, "Clinical characteristics and outcomes of post-COVID-19 pulmonary fibrosis:A case-control study", Medicine(Baltimore), 101(3), pp.e28639~ (2022)
- Lancaster LH, "Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosis", Eur Respir Rev, 26(146), pp.170057~ (2017)
- Lu ZH, "Efficacy of the combination of modern medicine and traditional Chinese medicine in pulmonary fibrosis arising as a sequelae in convalescent COVID-19 patients : a randomized multicenter trial", Infect Dis Poverty, 10(1), pp.31~ (2021)
- Rumende CM, "The Management of Pulmonary Fibrosis in COVID-19", Acta Med Indones, 53(2), pp.233~241 (2021)
- Hama Amin BJ, "Post COVID-19 pulmonary fibrosis; a meta-analysis study", Ann Med Surg(Lond), 77, pp.103590~ (2022)
- Kim Yoonjung, "Preliminary Guidelines for the Clinical Evaluation and Management of Long COVID", Infection and Chemotherapy, 54(3), pp.566~597 (2022), 대한감염학회[DOI]
- 전국한의과대학본초학교실, "본초학", pp.154~156 (2004), 영림사
- Ahn J, "The Effects of Lung-moistening Herbal Medicines on Bleomycin-induced Pulmonary Fibrosis Mouse Model", Processes, 8(1), pp.102~ (2020)
- Mathers CD, "Projections of Global Mortality and Burden of Disease from 2002 to 2030", PLoS Med, 3(11), pp.e442~ (2006)
- Spinou A, "An update on measurement and monitoring of cough: what are the important study endpoints?", J Thorac Dis, 6(Suppl 7), pp.S728~S734 (2014)
- 김진원, "통증척도 (VAS) 의 타당도 검증과 통증정도에 따른 신체활동량 기준치: 여성요통환자대상", 한국체육측정평가학회지, 15(2), pp.29~39 (2013), 한국체육측정평가학회[DOI]
- Devlin N, "Value Sets for EQ-5D-5L: A Compendium, Comparative Review & User Guide", pp.1~12 (2022), Springer
- 박종익, "한국판 일반 건강 설문지의 요인 구조", 신경정신의학, 51(4), pp.178~184 (2012), 대한신경정신의학회
- Bazdyrev E, "Lung Fibrosis after COVID-19: Treatment Prospects", Pharmaceuticals (Basel), 14(8), pp.807~ (2021)
- Doane JJ, "Progressive Pulmonary Fibrosis After Non-Critical COVID-19 : A Case Report", Am J Case Rep, 22, pp.e933458~ (2021)
- Rai DK, "Post covid 19pulmonary fibrosis. Is it real threat?", Indian J Tuberc, 68(3), pp.330~333 (2021)
- Hirawat R, "Lung fibrosis : Post-COVID-19complications and evidences", Int Immunopharmacol, 116, pp.109418~ (2023)
- Zou JN, "The characteristics and evolution of pulmonary fibrosis in COVID-19 patients as assessed by AI-assisted chest HRCT", PLoS One, 16(3), pp.e0248957~ (2021)
- Gulati A, "Interstitial lung abnormalities and pulmonary fibrosis in COVID-19 patients : a short-term follow-up case series", Clin Imaging, 77, pp.180~186 (2021)
- Lazar M, "Interstitial Lung Fibrosis Following COVID-19 Pneumonia", Diagnostics(Basel), 12(8), pp.2028~ (2022)
- 전국한의과대학 폐계내과학교실, "肺系內科學", pp.464~ (2019), 도서출판 나도
- 이경은, "코로나-19 환자의 후유증 한약 치료에 대한 고찰", 대한한방내과학회지, 42(1), pp.53~66 (2021), 대한한방내과학회[DOI]
- 류내형, "삼소음 알코올 추출물이 생쥐 면역세포의 시토킨 조절에 미치는 효과", 동의생리병리학회지, 22(4), pp.856~862 (2008), 한의병리학회
- Lyu Y, "Efficacy and Safety of Ojeok-San Plus Saengmaek-San for Gastroesophageal Reflux-Induced Chronic Cough : A Pilot, Randomized, Double-Blind, Placebo-Controlled Trial", Frontiers in Pharmacology, 13, pp.787860~ (2022)
- 남산당편집국, "對譯證脈,方藥合編", pp.136~137 (2003), 남산당
- 김주희, "LPS유도 염증 동물모델에서 오적산의 항염증 효과", 대한한의학회지, 42(2), pp.21~30 (2021), 대한한의학회
- Shin IS, "Ojeok-san, a Traditional Korean Herbal Medicine Attenuates Airway Inflammation and Pulmonary Fibrosis Induced by Repeated Ovalbumin challenge", J Ethnopharmacol, 149(1), pp.281~287 (2013)
- Ji K, "Efficacy and safety of traditional Chinese medicine in idiopathic pulmonary fibrosis : a meta-analysis", Evidence-Based Complementary and Alternative Medicine, 2020, pp.1~11 (2020)
- Li F, "An integrated pathway interaction network for the combination of four effective compounds from ShengMai preparations in the treatment of cardio-cerebral ischemic diseases", Acta Pharmacologica Sinica, 36(11), pp.1337~1348 (2015)
- Jang SB, "Telemedicine and the Use of Korean Medicine for Patients With COVID-19in South Korea : Observational Study", JMIR Public Health and Surveillance, 7(1), pp.e20236~ (2021)
- Chiang SC, "Antifibrotic effects of lilii bulbus extract in a mouse model of bleomycin-induced pulmonary fibrosis", Pharmacognosy Magazine, 17(76), pp.679~683 (2021)
- Liu WH, "Understanding of guidance for acupuncture and moxibustion interventions on COVID-19 issued by CAAM", World journal of acupuncture-moxibustion, 30(1), pp.1~4 (2020)
- 침구경혈학교실, "침구학" (1988), 집문당
- Li B, "Umbilical moxibustion for patients with idiopathic pulmonary fibrosis complicated with gastroesophageal reflux of lung-spleen qi deficiency", Chinese Acupuncture & Moxibustion, 39(3), pp.241~245 (2019)
- Cheng L, "Moxibustion has a positive effect on pulmonary fibrosis : an alternative approach", Afr J Tradit Complement Altern Med, 14(2), pp.125~129 (2017)
- Lechowicz K, "COVID-19 : The Potential Treatment of Pulmonary Fibrosis Associated with SARS-CoV-2 Infection", J Clin Med, 9(6), pp.1917~ (2020)